Deutsche Effecten- und Wechsel- Beteiligungsges. AG

Share Issue/Capital Change • Mar 23, 2006

News Details

Ad-hoc | 23 March 2006 10:40

Deutsche Effecten- und Wechsel- Beteiligungsges. AG: DEWB holding NOXXON wins Pfizer as a strategic Partner

Ad hoc announcement transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— – Long term technology and licence contracts between NOXXON and Pfizer. – Pfizer invests in NOXXON by means of a capital increase. – DEWB share in NOXXON after conversion of bonds at approx. 61 percent. Jena, 23. March 2006. NOXXON Pharma AG (NOXXON) today announced the closing of a strategic alliance with Pfizer Inc. (NYSE: PFE). NOXXON will, through the exploitation of their proprietary Spiegelmer® Technology, develop product candidates against disease associated Targets identified by Pfizer. Additionally Pfizer and NOXXON have signed a contract concerning an exclusive world-wide licence for the NOXXON Spiegelmer NOX-B11. NOX-B11 is a Ghrelin binding Spiegelmer, which has shown the ability in pre-clinical studies to curb appetite and induce weight loss and shall be developed for the treatment of obesity. NOXXON shall receive upfront payments as well as milestone payments from both agreements. Pfizer will, by means of a capital increase, concurrently make an equity investment in NOXXON. The DEWB has converted the convertible bonds issued by NOXXON in the years 2004 and 2005 into equity. After this conversion and the capital increase with regards to Pfizer the DEWB will hold a share of approx. 61 percent in NOXXON. Bertram Köhler, Member of the Management Board of DEWB, commented: ‘That NOXXON is able to conclude its first Corporate Deal with this large pharmaceutical company is evidence of the value of the Spiegelmer®- technology. This alliance with Pfizer is a great basis for the future development in the value of our investment.“ About DEWB: DEWB is a bank-independent, quoted investment company which operates internationally. The company is based in Jena, one of the booming high-tech regions of Germany especially in the field of optics. DEWB focuses on optic-related technologies that will be one of the most important technology drivers in the next years. As of Sept. 30th 2005 DEWB has assets of approx. 68 million euros under management and investments in appr. 15 companies. The 15.23 million bearer shares with a calculated nominal value of one euro per share are traded on the stock exchange in Frankfurt as well as in the Xetra system (www.dewb-vc.com; WKN 804 100 / ISIN DE0008041005 / symbol: EFF). About NOXXON Pharma AG the next generation aptamer company: Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word “Spiegel” means mirror) are highly specific for the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic – a new generation of improved therapeutics. Contact: Mirko Wäckerle Telephone: ++49 (0) 3641 65 21 58 Telefax: ++49 (0) 3641 65 21 57 E-Mail: ir@dewb-vc.com (c)DGAP 23.03.2006 ————————————————————————— language: English emitter: Deutsche Effecten- und Wechsel- Beteiligungsges. AG Carl-Zeiß-Platz 16 07743 Jena Deutschland phone: +49 (0)3641 65 2159 fax: +49 (0)3641 65 2157 email: ir@dewb-vc.com WWW: www.dewb-vc.com ISIN: DE0008041005 WKN: 804100 indexes: stockmarkets: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Stuttgart End of News DGAP News-Service —————————————————————————